Galiximab
- Generic Name
- Galiximab
- Drug Type
- Biotech
- CAS Number
- 357613-77-5
- Unique Ingredient Identifier
- S9OX9692ZB
- Background
Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
- Indication
Investigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.
Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT00651443
- Locations
- 🇺🇸
Research Site, Buffalo, New York, United States
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
Phase 3
Terminated
- Conditions
- Lymphoma, Non-Hodgkin's
- First Posted Date
- 2006-10-05
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 16
- Registration Number
- NCT00384150
A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)
Phase 3
Terminated
- Conditions
- Lymphoma, Non-Hodgkin's
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 340
- Registration Number
- NCT00363636
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath